Physician profile
Dou Huang
NPI 1316430242
$6,189.84
in general payments reported to CMS, 2019-2025
13 companies · $335 in 2025
The $335 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $151 · 2022: $493 · 2023: $186 · 2024: $5,025 · 2025: $335.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $4,500 · Food and Beverage: $646 · Education: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $4,500.00 |
| Food and Beverage | $646.03 |
| Education | $399.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $5,503.90 | 2021-2024 | Ensite, Thoratec Heartmate 3 Lvas Implant Kit |
| Alnylam Pharmaceuticals INC. | $134.76 | 2025 | Onpattro |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $130.06 | 2021-2024 | Lifevest |
| Novartis Pharmaceuticals Corporation | $120.16 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $57.97 | 2024-2025 | Verquvo |
| Janssen Pharmaceuticals, INC | $52.22 | 2024 | Xarelto |
| Abiomed | $44.16 | 2024 | |
| Amgen INC. | $31.75 | 2024 | Repatha |
| Cvrx, INC. | $28.52 | 2025 | Barostim Neo System |
| Actelion Pharmaceuticals US, INC. | $27.29 | 2025 | Opsumit |
| Scpharmaceuticals INC. | $22.24 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $21.56 | 2025 | Wainua |
| Pfizer INC. | $15.25 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dou Huang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.